Design and synthesis of a new series of 1,2,3-triazolyl-1,4-dihydropyridine hybrids (5a-5l) have been accomplished by a one-pot multicomponent reaction of opropargyl salicylaldehyde/o-propargyl naphthaldehyde, b-keto compounds, ammonium acetate, and organic azides in short reaction times. In vitro antibacterial studies of the newly synthesized hybrids were investigated against four different human pathogens, viz. S. aureus, Proteus mirabilis, E. Coli, and K. Pnemonia, and the results were compared with that of the standard drug, tetracycline. Also, their anti-inflammatory activity was studied against bovine serum albumin (BSA) and compared with that of the reference drug, dichlofenac. Some of the hybrids show good antibacterial and antiinflammatory activities comparable with that of the reference drugs.Electronic supplementary material The online version of this article (